Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno, C, Greil, R, Demirkan, F, Tedeschi, A, Anz, B, Larratt, L, Simkovic, M, Samoilova, O, Novak, J, Ben-Yehuda, D, Strugov, V, Gill, D, Gribben, JG, Hsu, E, Lih, CJ, Zhou, C, Clow, F, James, DF, Styles, L, Flinn, IW.

https://www.ncbi.nlm.nih.gov/pubmed/30522969